In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sarepta licenses EU rights to Summit's ezutromid for up to $952mm

Executive Summary

Sarepta Therapeutics Inc. gained exclusive EU rights to Summit Therapeutics PLC's oral utrophin modulator ezutromid (SMTC1100) for the muscle-wasting disease Duchenne muscular dystrophy (DMD). Sarepta's license also includes Switzerland, Norway, Iceland, Turkey, and the Commonwealth of Independent States, as well as an option to Latin American rights.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies